Abstract

IMPORTANCE Persons with opioid use disorder (OUD) and co-occurring alcohol use disorder (AUD) are understudied and undertreated. It is unknown whether the use of medications to treat OUD is associated with reduced risk of alcohol-related morbidity.

OBJECTIVE To determine whether the use of OUD medications is associated with decreased risk for alcohol-related falls, injuries, and poisonings in persons with OUD with and without co-occurring AUD.

DESIGN, SETTING, AND PARTICIPANTS This recurrent-event, case-control, cohort study used prescription claims from IBM MarketScan insurance databases from January 1, 2006, to December 31, 2016. The sample included persons aged 12 to 64 years in the US with an OUD diagnosis and taking OUD medication who had at least 1 alcohol-related admission. The unit of observation was person-day. Data analysis was performed from June 26 through September 28, 2020.

EXPOSURES Days of active OUD medication prescriptions, with either agonist (ie, buprenorphine or methadone) or antagonist (ie, oral or extended-release naltrexone) treatments compared with days without OUD prescriptions.

MAIN OUTCOMES AND MEASURES The primary outcome was admission for any acute alcohol-related event defined by International Classification of Diseases, Ninth Revision and International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes. Conditional logistic regression was used to compare OUD medication use between days with and without an alcohol-related event. Stratified analyses were conducted between patients with OUD with and without a recent AUD diagnostic code.

RESULTS There were 8 424 214 person-days of observation time among 13 335 participants who received OUD medications and experienced an alcohol-related admission (mean [SD] age, 33.1 [13.1] years; 5884 female participants [44.1%]). Agonist treatments (buprenorphine and methadone) were associated with reductions in the odds of any alcohol-related acute event compared with nontreatment days, with a 43% reduction for buprenorphine (odds ratio [OR], 0.57; 95% CI, 0.52-0.61) and a 66% reduction for methadone (OR, 0.34; 95% CI, 0.26-0.45). The antagonist treatment naltrexone was associated with reductions in alcohol-related acute events compared with nonmedication days, with a 37% reduction for extended-release naltrexone (OR, 0.63; 95% CI, 0.52-0.76) and a 16% reduction for oral naltrexone (OR, 0.84; 95% CI, 0.76-0.93). Naltrexone use was more prevalent among patients with OUD with recent AUD claims than their peers without AUD claims.

CONCLUSIONS AND RELEVANCE These findings suggest that OUD medication is associated with fewer admissions for alcohol-related acute events in patients with OUD with co-occurring AUD.

JAMA Network Open. 2021;4(2):e210061. doi:10.1001/jamanetworkopen.2021.0061
Introduction

Over the last decade, an unprecedented epidemic of drug-related poisonings has affected countries spanning North America and Europe. Recent estimates of unintentional poisoning deaths (19.1 deaths per 100,000) have eclipsed those of falls (11.4 deaths per 100,000) and motor vehicle traffic deaths (11.6 deaths per 100,000). This is evidenced by an all-time high of 70,980 overdose deaths in the US in 2019. Although the medical community has largely focused on the central role of opioid use disorder (OUD), polysubstance use has been underrecognized, even though most patients with substance use disorder use multiple substances, and the presence of multiple substance use disorders is associated with worse treatment outcomes.

Alcohol is the most commonly misused substance, both as a standalone drug and in the context of polysubstance use. More than 25% of patients with OUD exhibit problematic alcohol use, and, therefore, mitigation of risk for incident or recurrent alcohol use disorder (AUD) presents a salient problem in the treatment of OUD. As central nervous system depressants, alcohol and opioids can be lethal in combination, leading to increased overdoses and mortality among patients with OUD, in addition to increased health care utilization. Because problematic alcohol and opioid use are traditionally studied as independent conditions, limited evidence-based strategies exist for mitigation of alcohol-related risk among patients with OUD.

Despite the therapeutic challenge of treating alcohol and opioid co-use, there is reason to believe that existing OUD medications may hold promise in treating comorbid AUD, thus potentially reducing alcohol-related risk among patients with AUD. For instance, some treatment options for dual-diagnosis patients overlap, such as naltrexone, which holds dual US Food and Drug Administration (FDA) indications for OUD and AUD treatment and has been found to be used more commonly in patients with both OUD and AUD than patients with OUD but without comorbid AUD (Mintz CM, Presnall NJ, Xu KY, et al, unpublished data, November 2020). However, few studies have directly evaluated the efficacy of OUD medications on alcohol-related outcomes among patients with OUD, and the limited research base has been marked by inconsistent results. For instance, although an open randomized study suggested that methadone and buprenorphine suppressed alcohol intake in heroin users, other analyses have not replicated these effects, with some studies showing increased problematic use of alcohol after initiation of opioid agonist treatment. Existing studies are also characterized by short follow-up periods, modest sample sizes, and self-reported data.

Given the research gaps on alcohol-related outcomes among patients with OUD, our study used the IBM MarketScan Commercial and Multi-State Medicaid databases (2006-2016) to evaluate the association of 3 OUD medication treatments—buprenorphine, methadone, and naltrexone—with emergency and inpatient admissions for acute alcohol-related events, specifically falls, injuries, and poisonings in patients with OUD.

Methods

Study Overview

This case-control cohort study used a repeated-event, case-control design using the MarketScan pharmaceutical claims data. We studied whether alcohol-related acute medical events were associated with OUD pharmacologic treatment. This design used each subject as his or her own control by comparing OUD medication use (exposure) at the time of event with exposure during control periods. Thus, the exposure variable was various types of OUD pharmacologic treatments, and the outcome variable was alcohol-related acute events. We also examined whether patients with known recent AUD claims were more likely to receive naltrexone, given its dual FDA indications for AUD and OUD, as opposed to buprenorphine and methadone, and whether the association between OUD medication and alcohol-related events varies by the presence of recent AUD claims.
Study Setting
The MarketScan databases represent claims from both employer-sponsored and Medicaid insurance holders in the US.20 This captures longitudinal information on inpatient and outpatient health care utilization, diagnosis codes based on the *International Classification of Diseases, Ninth Revision (ICD-9)* and *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10)*, and procedure codes. Prescription medication data provided information on medication quantity, dosing, and fill dates. Commercial data were available from January 1, 2006, to December 31, 2016. Medicaid data were available from January 1, 2011, to December 31, 2016. Because all data were deidentified, our study was exempt from human subjects review and the need for informed consent by the institutional review board at Washington University. This study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) and RECORD-PE reporting guidelines.

Participants
Our analytic sample was derived from a previously described cohort of 304,676 individuals in the US, aged 12 to 64 years, who had prescription drug coverage, a diagnosis of OUD, at least 1 OUD claim during enrollment, and continuous insurance enrollment.20 Figure 1 depicts the derivation of our final analytical sample. Because we used a case-control design, we limited analyses to the 29,157 individuals with alcohol-related acute events (ie, 275,519 individuals were ineligible because they did not experience the outcome of interest). The first event for each person subsequent to initiating OUD treatment was defined as the index event. The index event date was used to generate a longitudinal data set at the day level containing all days in which a given individual was observed (ie, covered by insurance), up to 1 year before and after the index event; that is, the final data set contained 1 record per day per person, with the units of observation being person-days. Our decision to choose a 2-year maximum observation window was guided by the mean length of time individuals were observed in our data set, which was approximately 2 years. The selection of a standard, 2-year observation window also helps fulfill the case-control design’s requirement of a stable within-person probability of exposure over a defined period.21

Finally, we further limited our analyses to individuals who received OUD medication at least once, thus excluding 15,822 individuals who never received any pharmacotherapy for OUD (buprenorphine, naltrexone, and methadone). Participants were permitted to contribute multiple events as long as they fell within a maximum of 1 year before and after the index event.
Variables

Our primary outcome was emergency department visit or inpatient hospitalization for any alcohol-related acute event during insurance enrollment. Such events were defined on the basis of established methods and ICD-9 and ICD-10 codes as either (1) 100% alcohol-attributable acute events (e.g., alcohol poisoning) or (2) health care encounters involving an alcohol-related diagnosis (e.g., alcoholic liver disease or chronic alcohol dependence) in combination with acute events that are known to be associated with excess alcohol use (e.g., falls, injuries, and poisonings).22

Our primary exposure variable was OUD medication by days, operationalized as days characterized by the presence or absence of prescription coverage or procedure codes for buprenorphine, methadone, or naltrexone (oral or extended-release). Specific national drug codes (buprenorphine and oral naltrexone) and procedure codes (methadone and extended-release naltrexone) can be found elsewhere.20 We assumed that the prescription was filled on the date after the prescription was received by the pharmacy and taken until the last day supplied. We assumed that extended-release naltrexone was active for 28 days from the date of injection.

Because the MarketScan data do not differentiate between patients who were receiving naltrexone for OUD as opposed to AUD, we further stratified between patients with existing AUD diagnoses at the time of OUD pharmacologic treatment initiation or during the 6 months preceding treatment initiation, and those without recent AUD diagnoses. AUD diagnoses were identified by insurance claims using ICD-9 and ICD-10 codes during any inpatient or outpatient encounter.

For the purposes of sample description, we also obtained data on time-invariant variables, such as age, sex, and insurance status, which were compared among the subsamples with and without recent AUD claims. Because the case-control design allows for individuals to serve as their own control, we did not adjust for these time-invariant variables in our models. However, we included time-varying covariates corresponding to prescriptions for medications commonly found in alcohol and drug poisonings23; these included muscle relaxants, antispasmodics, opioids (not buprenorphine or methadone), antidepressants, mood stabilizers, antipsychotics, nonsteroidal anti-inflammatory drugs, and benzodiazepines (eTable 1 in the Supplement). The logic for including these was 2-fold. First, any interaction between these medications and OUD medications may be associated with the point estimates for the OUD medications. Second, use of these medications may serve as proxy variables for comorbidities that can be measured with greater frequency than diagnoses.

Statistical Analysis

We calculated descriptive statistics for the primary analytical sample using χ² and Kruskal-Wallis tests, which were stratified by recent AUD claims. For our primary analysis, we used a case-control approach described by Allison et al24 that includes all observed days limited to 365 days before and after the index alcohol-related acute event already described. Thus, case days included the index event and any subsequent event, whereas control days included all other days within the observation window. An overview of repeated-event, case-control design is illustrated in the eFigure in the Supplement. Models to estimate the odds ratio (OR) describing the association between events and OUD medication exposure days were estimated using conditional logistic regression, with each person serving as the stratification (conditioning) variable. Medication days were coded as 1, and nonmedication days were coded as 0 (reference group). This approach is analogous to a stratified Cox-regression with recurrent events.24 As a recurrent-event approach, our analysis allowed for incorporation of time (days since index event) as a covariate, mitigating secular confounding that is often a concern with single-event, case-control studies.24-26 We controlled for secular time trends using restricted cubic splines.27 Unadjusted models included only OUD medications, whereas adjusted models controlled for exposure medications commonly associated with alcohol poisonings.23 All P values were derived from 2-sided tests, with significance reached at P < .05. Statistical analysis was performed using SAS statistical software version 9.4 (SAS Institute) from June 26 through September 28, 2020.
Results

Sample and Treatment Characteristics

The final study sample contained 13,335 unique patients with OUD (mean [SD] age, 33.1 [13.1] years; 5884 female participants [44.1%]; mean observation time, 627.6 days; 8,424,214 person-days of observation time) who received OUD medications and had at least 1 alcohol-related acute event.

Table 1 summarizes descriptive statistics at the individual participant level, with stratification by the presence of recent AUD claims. In total, 19.6% of the sample (2,615 individuals) had claims for more than 1 event. Of all participants, 6,299 (47.2%) received buprenorphine in the year before and after the index event; in comparison, 667 (5.0%) received methadone, 1,096 (8.2%) received extended-release naltrexone, and 3,236 (24.3%) received oral naltrexone. Although all participants had received OUD medication during insurance enrollment, 2,037 (15.3%) did not receive OUD medication during the 1 year before and after index event that constituted our study's observation window.

A total of 55.9% of the sample (7,462 participants) had a recent AUD claim before or at start of OUD treatment, defined by diagnoses within 6 months of the start of treatment. These patients were

| Characteristic | Participants, No. (%) | OUD with recent AUD claims (n = 7,462) | OUD without recent AUD claims (n = 5,873) | P value |
|----------------|-----------------------|---------------------------------------|----------------------------------------|---------|
| OUD medication use during 1 y before and 1 y after index alcohol-related acute event | | | | |
| Buprenorphine | 6,299 (47.2) | 3,134 (42.0) | 3,165 (53.9) | <.001 |
| Methadone | 667 (5.0) | 298 (4.0) | 369 (6.3) | <.001 |
| Naltrexone extended release | 1,096 (8.2) | 737 (9.9) | 359 (6.1) | <.001 |
| Naltrexone oral | 3,236 (24.3) | 2,399 (32.2) | 837 (14.3) | <.001 |
| None | 2,037 (15.3) | 894 (12.0) | 1,143 (19.5) | <.001 |

Use of medications commonly found in association with alcohol poisonings during 1 y before and 1 y after index alcohol-related acute event

| Characteristic | Participants, No. (%) | OUD with recent AUD claims (n = 7,462) | OUD without recent AUD claims (n = 5,873) | P value |
|----------------|-----------------------|---------------------------------------|----------------------------------------|---------|
| Muscle relaxant | 4,579 (34.3) | 2,462 (33.0) | 2,117 (36.1) | <.001 |
| Antispasmodic | 1,667 (12.5) | 912 (12.2) | 755 (12.9) | .27 |
| Opioid (not or buprenorphine or methadone) | 8,543 (64.1) | 4,812 (64.5) | 3,731 (63.5) | .25 |
| Antidepressant | 10,533 (79.0) | 6,159 (82.5) | 4,374 (74.5) | <.001 |
| Mood stabilizer | 5,891 (44.2) | 3,790 (50.8) | 2,101 (35.8) | <.001 |
| Antipsychotic | 5,938 (44.5) | 3,521 (47.2) | 2,417 (41.2) | <.001 |
| Nonsteroidal anti-inflammatory drug | 6,312 (47.3) | 3,583 (48.0) | 2,729 (46.5) | .08 |
| Benzodiazepine | 7,552 (56.6) | 4,359 (57.7) | 3,193 (42.3) | <.001 |

Sociodemographic characteristics

| Characteristic | Participants, No. (%) | OUD with recent AUD claims (n = 7,462) | OUD without recent AUD claims (n = 5,873) | P value |
|----------------|-----------------------|---------------------------------------|----------------------------------------|---------|
| Sex | | | | |
| Male | 7,451 (55.9) | 4,235 (56.8) | 3,216 (54.7) | .02 |
| Female | 5,884 (44.1) | 3,227 (43.3) | 2,657 (45.2) | |
| Insurance | | | | |
| Private insurance | 9,276 (69.6) | 5,322 (71.3) | 3,954 (67.3) | <.001 |
| Medicaid | 4,059 (30.4) | 2,140 (28.7) | 1,919 (32.7) | |
| Year of birth | 1,977 | 1,975 | 1,979 | |
| Age, mean (SD), y | 33.1 (13.1) | 34.9 (12.9) | 30.8 (13.1) | <.001 |
| Alcohol-related acute events, No. | | | | |
| 1 | 10,720 (80.4) | 5,501 (73.7) | 5,219 (88.9) | |
| 2 | 1,639 (12.3) | 1,167 (15.6) | 472 (8.0) | <.001 |
| ≥3 | 976 (7.3) | 794 (10.6) | 182 (3.1) | |

Abbreviations: AUD, alcohol use disorder; OUD, opioid use disorder.

* This table illustrates OUD treatment characteristics at the individual participant level among those with a history of alcohol-related acute events during the study's observation window (1 year before and after index event), stratified by recent AUD claims. The prevalence of using specific medications of interest within the study’s observation period is also depicted. The bottom of the table depicts demographic characteristics for participants, as well as number of alcohol-related acute events.
less likely to receive agonist therapy than their peers without AUD claims (42.0% [3134 participants] vs 53.9% [3165 participants] for buprenorphine; 4.0% [298 participants] vs 6.3% [369 participants] for methadone). Conversely, they were more likely to receive naltrexone (oral naltrexone, 32.2% [2399 participants] vs 14.3% [837 participants]; extended-release naltrexone, 9.9% [737 participants] vs 6.1% [359 participants]). With regard to sociodemographic characteristics, individuals with recent AUD claims were slightly older (mean [SD] age, 34.9 [12.9] vs 30.8 [13.1] years), more likely to be male (4235 [56.8%] vs 3216 [54.7%] men), less likely to be enrolled in Medicaid (2140 [28.7%] vs 1919 [32.7%] participants), and were more likely to incur multiple alcohol-related events (1967 [26.2%] vs 654 [11.1%] events) (Table 1). Participants with recent AUD claims also had more prescriptions for antidepressants (6156 [82.5%] vs 4374 [74.5%] participants), mood stabilizers (3790 [50.8%] vs 2101 [35.8%] participants), antipsychotics (3521 [47.2%] vs 2417 [41.2%] participants), and benzodiazepines (4359 [57.7%] vs 3193 [42.2%] participants) than participants without AUD claims.

Table 2 depicts the rate of alcohol-related events, per 100 days, stratified by OUD medication exposure and by recent AUD claims. In general, event rates were lower for buprenorphine or methadone treatment days than for days when patients were treated with either naltrexone formulation or for nonmedication days. For nontreatment days, 0.22% of days overall (mean, 535.0 days per person), 0.25% of days for those with active AUD claims (mean, 534.6 days per person), and 0.18% of days among those without active AUD claims (mean, 535.6 days per person) were marked by alcohol-related acute events. For antagonist medications, 0.29% (mean, 15.7 days per person) of oral naltrexone treatment days (0.28% [mean, 8.2 days per person] for those with active AUD claims and 0.29% [mean, 21.5 days per person] for those without active AUD claims) and 0.19% (mean, 6.4 days per person) of extended-release naltrexone treatment days (0.20% [mean, 7.5 days per person] for those with AUD claims and 0.18% [mean, 5.1 days per person] for those without AUD claims) were marked by events. Among agonist medications, 0.11% (mean, 8.4 days per person) of methadone treatment days (0.11% [mean, 5.8 days per person] of days for those with AUD claims and 0.12% [mean, 11.7 days per person] of days for those without AUD claims) and 0.15% (mean, 62.7 days per person) of buprenorphine treatment days (0.13% of days [mean, 48.9 days per person] for those with AUD claims and 0.16% [mean, 80.3 days per person] for those without AUD claims) were marked by alcohol-related acute events.

### Association of OUD Medication With Alcohol-Related Acute Events

Figure 2 shows the adjusted ORs for admissions for alcohol-related acute events associated with days using OUD medications vs nonmedication days. A full listing of point estimates and 95% CIs is enumerated in eTable 2 (unadjusted models) and eTable 3 (adjusted models) in the Supplement, with...
the association between OUD medication and alcohol-related acute events unchanged between unadjusted and adjusted analyses. Covariate adjustment had little impact on the other parameters in the model. Among agonist medications, buprenorphine was associated with a 43% reduction (OR, 0.57; 95% CI, 0.52-0.61) and methadone was associated with a 66% reduction (OR, 0.34; 95% CI, 0.26-0.45) in adjusted odds of alcohol-related acute events. Among antagonist medication, oral naltrexone was associated with a 37% reduction (OR, 0.63; 95% CI, 0.52-0.76) and extended-release naltrexone was associated with a 16% reduction (OR, 0.84; 95% CI, 0.76-0.93) in the adjusted odds of such events.

In the stratified analysis, buprenorphine's protective associations against alcohol-related acute events were more pronounced among patients with OUD with recent AUD claims (OR, 0.41; 95% CI, 0.36-0.46) than among peers without such claims (OR, 0.74; 95% CI, 0.66-0.83). In comparison, methadone exhibited similar protective associations in patients with OUD with (OR, 0.30; 95% CI, 0.20-0.45) and without (OR, 0.36; 95% CI, 0.25-0.53) recent AUD claims. The protective associations of extended-release naltrexone (OR, 0.56; 95% CI, 0.45-0.70) and oral naltrexone (OR, 0.79; 95% CI, 0.70-0.88) were significant only among patients with OUD with AUD, as opposed to peers without claims; however, differences in adjusted ORs by AUD status were not significant because of wide 95% CIs among patients with AUD. Across all analyses, the 2 forms of naltrexone did not significantly differ from one another in their association with alcohol-related acute events.

**Discussion**

Our study shows that OUD treatment days were associated with reductions in overall odds of admissions for alcohol-related acute events (ie, falls, injuries, and poisonings). We observed risk reductions of 43% for buprenorphine and 66% for methadone treatment days. Extended-release and oral naltrexone treatment days were associated with 37% and 16% reductions, respectively. Naltrexone use was more prevalent among patients with OUD with existing AUD claims than their peers without such claims, consistent with naltrexone's dual FDA indications of naltrexone for both AUD and OUD treatment. However, naltrexone and buprenorphine showed similar overall protective outcomes against alcohol-related acute events.

Interestingly, our findings illustrate that the greatest overall reduction in alcohol-related acute events were observed with methadone. Time-varying confounding cannot be ruled out because
these results can be partly explained by the structure of opioid treatment programs (ie, methadone clinics), which frequently monitor alcohol and illicit drug use with urine drug screens. The effectiveness of OUD medications in AUD may be more limited when it is not accompanied by psychosocial interventions, such as relapse-prevention therapy or counseling focused on medication adherence, which are seen in opioid treatment programs that dispense methadone. The association between methadone treatment days and alcohol-related events warrants further investigation.

Of note, our results should be interpreted in conjunction with known differences in medication adherence. The true practical effectiveness of antagonist therapies may be hindered by lower medication adherence associated with naltrexone compared with agonist treatments in the OUD population. For instance, substantially greater medication adherence has been observed for buprenorphine treatment (median filled prescriptions of 19 months) compared with both extended-release (9 months) and oral (5 months) naltrexone, with patients with OUD found to show similar adherence to methadone and buprenorphine. As our study evaluates ORs that describe protective outcomes associated with medication at a given point in time, the protective outcomes observed in association with buprenorphine and methadone treatment days are likely to be amplified by their higher adherence rates compared with naltrexone. However, our analyses rely on the implicit assumption that risks associated with medication or lack of medication are constant over time. More investigation is needed to evaluate how these risks might vary before, during, and after OUD treatment, in addition to investigating the comparative effectiveness of buprenorphine, methadone, and naltrexone in suppressing alcohol use in patients with OUD.

Limitations and Strengths
There are several limitations to note. First, although the MarketScan data benefit from a large, national sample with ample longitudinal follow-up, measurement error cannot be ruled out, such that medication coverage does not always reflect actual consumption. Furthermore, patients with OUD without observed AUD claims may have a history of treated or untreated AUD not reflected in recent insurance claims. However, we observed a higher prevalence of naltrexone use in patients with AUD claims, and we also observed significant differences in OUD medication treatment outcomes between patients with OUD with recent AUD claims and peers without such claims, suggesting that the distinction between these 2 groups may be clinically meaningful and thus warrants more research. Second, unmeasured time-varying factors associated with alcohol-related admissions and OUD medication exposure can introduce confounding in case-control designs. We mitigated this, however, by including calendar time and time from event as covariates and restricting participants to 2-year observation periods surrounding the index event in order to reduce heterogeneity in observation time. We also used bidirectional sampling in order to reduce overlap bias resulting from control period selection as a function of event time. Third, even though self-matching is used by the case-control design, residual confounding by unmeasured time-invariant variables cannot be ruled out. Fourth, the MarketScan data only encompass insured patients with observed alcohol-related acute events, which limits our study’s generalizability.

Despite these limitations, our study was strengthened by its repeated-event, case-control design, allowing for reduction of selection and sampling bias stemming from conventional observational study recruitment. In addition, we controlled for conditions leading to alcohol-related events via adjustment for medications commonly found in association with such events. The protective associations of buprenorphine, methadone, and naltrexone were not significantly changed in the adjusted analyses, providing evidence of robustness to measured confounders.

Conclusions
The findings of this study suggest that OUD medications are associated with decreased hospital admissions for alcohol-related acute events among persons with OUD. Although naltrexone use was
more prevalent among patients with OUD with recent AUD claims, agonist treatments
(buprenorphine and methadone) also were associated with fewer alcohol-related events. The
present study raises key questions about the potential of OUD medications for reducing alcohol-
related events and highlights the need for additional research in this area.

ARTICLE INFORMATION

Accepted for Publication: January 1, 2021.

Published: February 24, 2021. doi:10.1001/jamanetworkopen.2021.0061

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2021 Xu KY et al. JAMA Network Open.

Corresponding Author: Kevin Y. Xu, MD, MPH, Health and Behavior Research Center, Department of Psychiatry, Washington University School of Medicine in St Louis, 420 S Euclid Ave, Campus Box 8134, St Louis, MO 63110 (xukeviny@wustl.edu).

Author Affiliations: Health and Behavior Research Center, Department of Psychiatry, Washington University School of Medicine in St Louis, St Louis, Missouri (Xu, Presnall, Mintz, Borodovsky, Bhat, Bierut, Grucza); Now with Center for Technology and Behavioral Health, Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, New Hampshire (Borodovsky); Alvin J Siteman Cancer Center, Barnes Jewish Hospital and Washington University School of Medicine in St Louis, St Louis, Missouri (Bierut); Department of Family and Community Medicine, St Louis University, St Louis, Missouri (Grucza); Department of Health and Clinical Outcomes Research, St Louis University, St Louis, Missouri (Grucza).

Author Contributions: Drs Xu and Grucza had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Xu, Presnall, Mintz, Grucza.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Xu, Bhat, Grucza.

Critical revision of the manuscript for important intellectual content: Xu, Presnall, Mintz, Borodovsky, Bierut, Grucza.

Statistical analysis: Xu, Presnall, Borodovsky, Grucza.

Obtained funding: Grucza.

Administrative, technical, or material support: Mintz, Bhat, Grucza.

Supervision: Borodovsky, Bierut, Grucza.

Conflict of Interest Disclosures: Dr Borodovsky reported serving on the board of directors and being treasurer of the nonprofit MySafeRx, Inc but does not receive any financial compensation for this work. Dr Bierut reported being listed as an inventor on US Patent 8080371, Markers for Addiction, covering use of single-nucleotide polymorphisms in determining the diagnosis, prognosis, and treatment of addiction. No other disclosures were reported.

Funding/Support: This work was supported by the National Institutes of Health (grant R25 MH112473-01 to Dr Xu, grant K12 DA041449 to Dr Mintz, grants R21 AA02568901 and F32 AA027941 to Dr Borodovsky, grants U01 AA008401 and R01 DA036583 to Dr Bierut, and grant R21 DA044744 to Dr Grucza). Nuri Farber, MD, provided funding via the Psychiatry Residency Research Education Program of Washington University.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Disclaimer: IBM Watson Health and MarketScan are trademarks of IBM Corporation in the United States, other countries, or both.

Additional Contributions: John Sahrmann, MA, and the Center for Administrative Data Research (CADR) at Washington University provided assistance with data acquisition, management, and storage (Mr Sahrmann was not compensated for this contribution). A cleaned version of data was provided to the authors by CADR. No data linkage was conducted by the authors. The authors did not access the database population used to create the study population, which is secured by CADR. CADR is supported in part by the Washington University Institute of Clinical and Translational Sciences via grants UL1 TR002345 (from the National Center for Advancing Translational
REFERENCES

1. Centers for Disease Control and Prevention, National Center for Health Statistics. FactStats: accidents or unintentional injuries. Updated November 13, 2020. Accessed January 21, 2021. https://www.cdc.gov/nchs/fastats/accidental-injury.htm

2. Ahmad FB, Rossen LM, Sutton P; National Center for Health Statistics. Provisional drug overdose death counts. Published 2020. Accessed January 21, 2021. https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm

3. Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244-250. doi:10.2105/AJPH.2019.305412

4. Degenhardt L, Grebely J, Stone J, et al. Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 2019;394(10208):1560-1579. doi:10.1016/S0140-6736(19)32229-9

5. Hassan AN, Le Foll B. Polydrug use disorders in individuals with opioid use disorder. Drug Alcohol Depend. 2019;198:28-33. doi:10.1016/j.drugalcdep.2019.01.031

6. Wang L, Min JE, Krebs E, et al. Polydrug use and its association with drug treatment outcomes among primary heroin, methamphetamine, and cocaine users. Int J Drug Policy. 2017;49:32-40. doi:10.1016/j.drugpo.2017.07.009

7. Gomes T, Khoo W, Martins D, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ. 2018;362:k3207. doi:10.1136/bmj.k3207

8. Jones CM, McCance-Katz EF. Co-occurring substance use and mental disorders among adults with opioid use disorder. Drug Alcohol Depend. 2019;197:78-82. doi:10.1016/j.drugalcdep.2018.12.030

9. Winstanley EL, Stover AN, Feinberg J. Concurrent alcohol and opioid use among harm reduction clients. Addict Behav. 2020;100:106027. doi:10.1016/j.addbeh.2019.06.016

10. White JM, Irvine RJ. Mechanisms of fatal opioid overdose. Addict. 1999;94(7):961-972. doi:10.1046/j.1360-0443.1999.9479612.x

11. Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, 1990-98. Addiction. 2003;98(6):739-747. doi:10.1046/j.1360-0443.2003.00376.x

12. Hser YI, Mooney LJ, Saxon AJ, et al. High mortality among patients with opioid use disorder in a large healthcare system. J Addict Med. 2017;11(4):315-319. doi:10.1097/ADM.0000000000000312

13. Frank D, Mateu-Gelabert P, Guarino H, et al. High risk and little knowledge: overdose experiences and knowledge among young adult nonmedical prescription opioid users. Int J Drug Policy. 2015;26(1):84-91. doi:10.1016/j.drugpo.2014.07.013

14. Hickman M, Lingford-Hughes A, Bailey C, Macleod J, Nutt D, Henderson G. Does alcohol increase the risk of overdose death: the need for a translational approach. Addiction. 2008;103(7):1060-1062. doi:10.1111/j.1360-0443.2008.02134.x

15. Witkiewitz K, Vowles KE. Alcohol and opioid use, co-use, and chronic pain in the context of the opioid epidemic: a critical review. Alcohol Clin Exp Res. 2018;42(3):478-488. doi:10.1111/acer.13594

16. Soysa M. Alcohol use disorders in opioid maintenance therapy: prevalence, clinical correlates and treatment. Eur Addict Res. 2015;21(2):78-87. doi:10.1159/000363232

17. Srivastava A, Kahan M, Ross S. The effect of methadone maintenance treatment on alcohol consumption: a systematic review. J Subst Abuse Treat. 2008;34(2):215-223. doi:10.1016/j.jsat.2007.04.001

18. Dong H, Hayashi K, Milloy MJ, et al. Changes in substance use in relation to opioid agonist therapy among people who use drugs in a Canadian setting. Drug Alcohol Depend. 2020;212:108005. doi:10.1016/j.drugalcdep.2020.108005

19. Caputo F, Addolorato G, Domenicali M, et al; Services for Addiction Treatment. Short-term methadone administration reduces alcohol consumption in non-alcoholic heroin addicts. Alcohol Alcohol. 2002;37(2):164-168. doi:10.1093/alc alc/37.2.164

20. Mintz CM, Pressnall NJ, Sahrnam JM, et al. Age disparities in six-month treatment retention for opioid use disorder. Drug Alcohol Depend. 2020;213:108130. doi:10.1016/j.drugalcdep.2020.108130

21. Wang SV, Gagne JJ, Glynn RJ, Schneeweiss S. Case-crossover studies of therapeutics: design approaches to addressing time-varying prognosis in elderly populations. Epidemiology. 2013;24(3):375-378. doi:10.1097/EDE.Ob013e31828ac9cb

22. Centers for Disease Control and Prevention. Alcohol-related disease impact (ARDI) application. Updated September 3, 2020. Accessed January 21, 2021. https://nccd.cdc.gov/DPH_ARDl/default/default.aspx
23. Castle JJ, Dong C, Haughwout SP, White AM. Emergency department visits for adverse drug reactions involving alcohol: United States, 2005 to 2011. *Alcohol Clin Exp Res.* 2016;40(9):1913-1925. doi:10.1111/acer.13167

24. Allison P, Christakis N. Fixed-effects methods for the analysis of nonrepeated events. *Sociol Methodol.* 2006;36(1):155-172. doi:10.1111/j.1467-9531.2006.00177.x

25. Mittleman MA, Mostofsky E. Exchangeability in the case-crossover design. *Int J Epidemiol.* 2014;43(5):1645-1655. doi:10.1093/ije/dyu081

26. Hallas J, Pottegård A, Wang S, Schneeweiss S, Gagne JJ. Persistent user bias in case-crossover studies in pharmacoepidemiology. *Am J Epidemiol.* 2016;184(10):761-769. doi:10.1093/aje/kww079

27. Jensen AK, Gerds TA, Weeke P, Torp-Pedersen C, Andersen PK. On the validity of the case-time-control design for autocorrelated exposure histories. *Epidemiology.* 2014;25(1):110-113. doi:10.1097/EDE.0000000000000001

28. Dugosh K, Abraham A, Seymour B, McLoyd K, Chalk M, Festinger D. A systematic review on the use of psychosocial interventions in conjunction with medications for the treatment of opioid addiction. *J Addict Med.* 2016;10(2):93-103. doi:10.1097/ADM.0000000000000193

29. Morgan JR, Schackman BR, Weinstein ZM, Walley AV, Linas BP. Overdose following initiation of naltrexone and buprenorphine medication treatment for opioid use disorder in a United States commercially insured cohort. *Drug Alcohol Depend.* 2019;200:34-39. doi:10.1016/j.drugalcdep.2019.02.031

30. Kinsky S, Houck PR, Mayes K, Loveland D, Daley D, Schuster JM. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: a view from the payer perspective. *J Subst Abuse Treat.* 2019;104:15-21. doi:10.1016/j.jsat.2019.05.015

**SUPPLEMENT.**

eTable 1. Classification of Medications Commonly Found in Association With Alcohol Poisoning
eTable 2. Odds of Alcohol-Related Acute Events Associated with OUD Medication Treatment Days Without Adjustment for Treatment Days Encompassing Medications Commonly Found in Association With Alcohol Poisoning
eTable 3. Odds of Alcohol-Related Acute Events Associated With OUD Medication Treatment Days, With Adjustment for Treatment Days Encompassing Medications Commonly Found in Association with Alcohol Poisoning
eFigure. Overview of Case-Crossover Design